All Stories

  1. Science and Engineering Ethics Enters its Third Decade
  2. On the Use of the Concept of “Fairness” in the World of Vaccines and Vaccination
  3. What is excellent science and how does it relate to what we publish in vaccine?
  4. On Cheating
  5. On the Use of the Concept of “Fairness” in Ethics
  6. Preface to Volume 00 of the Procedia in Vaccinology
  7. Introductory editorial
  8. Editorial
  9. Animal Cell Technology: Historical Introduction
  10. Ethical Issues in Animal and Plant Cell Technology
  11. “Dual Use” and “Intentionality”: Seeking to Prevent the Manifestation of Deliberately Harmful Objectives
  12. On the Ethics of Using Citation Indices in Evaluations
  13. Facing up to Creating Life: Synthetic Biology Unfolds its Wings
  14. 1st International Pneumonia Vaccines Workshop Seoul, 15 December 2007
  15. A Conflict of Interest Disclosure Policy for Science and Engineering Ethics
  16. Climate—An Item for the Ethics Agenda
  17. Some Thoughts on the 2007 World Conference on Research Integrity
  18. Science and Engineering Ethics at Springer
  19. Reflections on the Budapest meeting 2005 of the European ethics consortium
  20. Conference summary: ‘The responsible conduct of basic and clinical research’
  21. The british public speaks
  22. Observations on a meeting on the ethics of intellectual property rights and patents
  23. Editorial — Words are tools
  24. Human genetic testing under examination by the European Union
  25. Placebo: Its action and place in health research today* — Summary and conclusions
  26. On the management of funding of research in science and engineering
  27. Additional thoughts on the funding of poliovirus research: Some reflections stimulated by “parallel path: Poliovirus research in the vaccine era” (M.S. Garfinkel and D. Sarewitz)
  28. Encyclopedia of Cell Technology
  29. On dealing with bias
  30. Reflections on ‘Real science: What it is, and what it means’ by John Ziman
  31. Peer review and innovation
  32. Genes in court
  33. Reflections (3 of 4)
  34. Scientific misconduct: Ongoing developments
  35. On a question of trust
  36. Reflections on the 4th world congress of bioethics
  37. Book review
  38. An approach to the ethics of cloning humans via an examination of the ethical issues pertaining to the use of any tool
  39. Communicating to the public via the media: Practical and ethical issues
  40. Ethics and the funding of research and development at universities
  41. Ethics for science and engineering based international industries
  42. The Human Genome Project under the microscope
  43. Book reviews
  44. Ethical issues in research relationships between universities and industry
  45. Making human tissues acceptable
  46. Ethical aspects of the university-industry interface
  47. Welcome to science and engineering ethics
  48. Science, engineering and ethics: Running definitions
  49. Genetic engineering of hybridoma glutamine metabolism
  50. CHAIRMAN'S STATEMENT
  51. Large-scale mammalian cell culture: methods, applications and products
  52. Monoclonal Antibodies in Biology and Biotechnology: Theoretical and Practical Aspects. Kenneth C. McCullough Raymond E. Spier
  53. Small molecules, large molecules, and the new biotechnology
  54. Monoclonal antibodies in biology and biotechnology:theoretical and practical aspects
  55. Editorial
  56. Technology of Mass Cultivation: An Overview
  57. Cytometabolism diffusion test (CMDT) for the determination of animal cell bioreactor parameters
  58. ‘Vaccine’ expands
  59. Dense cultures of animal cells at the industrial scale
  60. Growth promoting materials derived from HeLa cell culture supernatants
  61. Safety in biotechnology
  62. Editorial
  63. The adhesion of animal cells to surfaces: The measurement of critical surface shear stress permitting attachment or causing detachment
  64. Animal cell technology: An overview
  65. References
  66. Recent developments in the large scale cultivation of animal cells in monolayers
  67. Introduction: the immune response
  68. Making hybridomas (hybridoma technology)
  69. Factors affecting successful hybridoma production
  70. Selection of monoclonal antibody-secreting hybridoma cell lines
  71. The large-scale production of monoclonal antibodies in vitro
  72. In conclusion: the diversity in application of monoclonal antibodies and hybridoma technology